This Medudy course is a video tutorial for physicians on the topic of "Elafibranor in primary biliary cholangitis". The format used here is a so-called "Journal Club Summary", in which we summarize the latest and most clinically relevant studies for you.
Primary biliary cholangitis is a rare, chronic cholestatic liver disease characterized by progressive destruction of the interlobular bile ducts, and if left untreated, primary biliary cholangitis can progress to cirrhosis, require liver transplantation and lead to premature death. Elafibranor is an oral dual agonist of the peroxisome proliferator-activated receptors PPAR-α and PPAR-δ, which modulates the transcription of bile acid homeostasis and inflammation genes. In this way, toxic effects of bile acid and the inflammatory response can be reduced. However, the efficacy of elafibranor in primary biliary cholangitis has not yet been proven. Today's study was therefore designed to answer this question.
Note: All "speakers" appearing in the Medudy videos are AI-based avatars used to improve the didactics of the videos. The people on whom the avatars are based have explicitly consented to their use. All content is based on high-quality scientific sources and is created and reviewed by the Medudy medical team.
At the end of this course you will know
- the clinical background and relevance of the research question under investigation
- the study design and methodology of the publication to answer the research question
- the results and key takeaways of the publication
- the conclusion of the publication and possible limitations
